BRIEF—ICER to review treatments for peanut allergy

The USA’s Institute for Clinical and Economic Review (ICER) has posted a Draft Scoping Document outlining a planned review of the comparative clinical effectiveness and value of treatments for peanut allergy.

This evidence review will examine two new technologies to induce immune tolerance – Viaskin Peanut, from DBV Technologies, and AR101, from Aimmune Therapeutics – as well as non-commercialized oral immunotherapy (OIT).

On June 11, 2019, the ICER’s report will be the subject of a meeting of the California Technology Assessment Forum, one of the ICER’s three independent evidence appraisal committees.

All interested stakeholders are encouraged to submit comments and suggested refinements to the scope to ensure all perspectives are adequately considered. Comments can be submitted by email to publiccomments@icer-review.org and must be received by 5 PM ET on December 12, 2018.